A practical reference on 胸腺素α1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-29. Anything still debated is marked as such rather than presented as settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Samsung stated that the silver gets washed away in the sewer and regulatory agencies worry over what that means for wastewater treatment streams. Currently, the EPA classifies silver nanoparticles as pesticides due to their use as antimicrobial agents in wastewater purification. The washing machines being developed by Samsung do contain a pesticide and have to be registered and tested for safety under the law, particularly the U.S. Federal Insecticide, Fungicide, and Rodenticide Act. The difficulty, however behind regulating nanotechnology in this manner is that there is no distinct way to measure toxicity.
Data from the Office for National Statistics shows a 3.4% increase in retail sales during January 2024, largely fuelled by food shopping and the January sales. Amina Noor, who took a three-year-old British girl to Kenya for female genital mutilation in 2005, is sentenced to seven years in prison following a trial at the Old Bailey. She becomes the first person to be convicted in the UK for assisting a non-UK person to carry out the practice. Prince William announces plans to build 24 homes on Duchy of Cornwall land to help tackle homelessness. The prince wants to end homelessness as part of a major five-year campaign launched in 2023. 18 February – Senior police officers condemn "sexist and homophobic" comments made online about Karen Findlay, the newly appointed deputy chief constable of British Transport Police, following news of her promotion. 19 February gov.uk updates the Royal Cypher Crown, replacing Queen Elizabeth II's St Edward's Crown with the Tudor Crown used by King Charles III. Following a trial at Canterbury Crown Court, Senegalese national Ibrahima Bah is found guilty of the manslaughter of four migrants when the boat he was steering ran into trouble in the English Channel. Bah had agreed to steer the boat in exchange for a free crossing in December 2022. Thomas Salton of Basildon, Essex becomes the first person in the UK to be convicted of possession and intent to supply nitrous oxide, and is sentenced to four months in prison.
=== Pleural space pressure === A pneumothorax (collapsed lung) is an abnormal collection of air in the pleural space that causes an uncoupling of the lung from the chest wall. The lung cannot expand against the air pressure inside the pleural space. An easy to understand example is a traumatic pneumothorax, where air enters the pleural space from outside the body, as occurs with puncture to the chest wall. Similarly, scuba divers ascending while holding their breath with their lungs fully inflated can cause air sacs (alveoli) to burst and leak high pressure air into the pleural space.
== Near-patient testing == In addition to the laboratory method outlined above, near-patient testing (NPT) or home INR monitoring is becoming increasingly common in some countries. In the United Kingdom, for example, near-patient testing is used both by patients at home and by some anticoagulation clinics (often hospital-based) as a fast and convenient alternative to the lab method. After a period of doubt about the accuracy of NPT results, a new generation of machines and reagents seems to be gaining acceptance for its ability to deliver results close in accuracy to those of the lab.
== Selected publications == Steven Ruggles. 2026. The Pig in the Python: U.S. Labor Flows and Economic Opportunity, 1910-2040. Proceedings of the National Academy of Sciences, 123(20): e2601716123. Steven Ruggles. 2025. The Shortcomings of Synthetic Census Microdata for Social Science Research. Proceedings of the National Academy of Sciences, 122(11): e2424655122. Steven Ruggles. 2024. When Privacy Protection Goes Wrong: How and Why the 2020 Census Confidentiality Program Failed. Journal of Economic Perspectives 38(2) 201-226 Steven Ruggles and Diana Magnuson. 2023. 'It’s none of their damn business': Privacy and Disclosure Control in the U.S. Census, 1790-2020. Population and Development Review 49(3): 651-679 Steven Ruggles. 2021. The Revival of Quantification: Reflections on Old New Histories. Social Science History. 45: 1-25. Ruggles, Steven and Diana L. Magnuson. Census Technology, Politics, and Institutional Change, 1790–2020. Journal of American History vol. 107 (2020), pp. 19-51 Ruggles, Steven. Patriarchy, Power, and Pay: The Transformation of American Families, 1800–2015. Demography, vol. 52 (2015), pp. 1797-1823 Ruggles, Steven. Big Microdata for Population Research. Demography, vol. 51 (2014), pp. 287-297 Kennedy, Sheela and Steven Ruggles. Breaking up is Hard to Count: The Rise of Divorce in the United States, 1980–2010.Demography, vol. 51 (2014), pp. 587–598 Ruggles, Steven. Reconsidering the Northwest European Family System. Population and Development Review, vol. 35 (2009), pp. 321–332 Ruggles, Steven.
Sources: en.wikipedia.org
== Applications == Biotechnological applications of selenocysteine include use of 73Se-labeled Sec (half-life of 73Se = 7.2 hours) in positron emission tomography (PET) studies and 75Se-labeled Sec (half-life of 75Se = 118.5 days) in specific radiolabeling, facilitation of phase determination by multiwavelength anomalous diffraction in X-ray crystallography of proteins by introducing Sec alone, or Sec together with selenomethionine (SeMet), and incorporation of the stable 77Se isotope, which has a nuclear spin of 1/2 and can be used for high-resolution NMR, among others.
==== Hollow MNPs ==== Among all of the MNPs, hollow needles allow a bigger amount of delivery up to 200μL. The mechanism mimics the operation of a hypodermic, but the fabrication is hard and complex. The hollow needles introduce a potential failure if the insertion is improper. That is why, among the others, hollow MNPs are the least popular because of the complex manufacturing and applying process.
Teva and Sandoz are by far the largest generics companies. They differ from their competitors not only in sales revenues but also because they are backwards integrated and have proprietary drugs in their portfolios. They also vie for the biosimilars market. Several thousand small or virtual pharma companies focus on R&D of just a few lead compounds. They typically originate mostly from academia. Therefore, their R&D strategy is more focused on the elucidation of the biological roots of diseases rather than developing synthesis methods.
== Chemistry == Clorazepate is used in the form of a dipotassium salt. It is unusual among benzodiazepines in that it is freely soluble in water. Clorazepate can be synthesized starting from 2-amino-5-chlorobenzonitrile, which upon reaction with phenylmagnesium bromide is transformed into 2-amino-5-chlorbenzophenone imine. Reacting this with aminomalonic ester gives a heterocyclization product, 7-chloro-1,3-dihydro-3-carbethoxy-5-phenyl-2H-benzodiazepin-2-one. Upon hydrolysis using an alcoholic solution of potassium hydroxide forms a dipotassium salt, chlorazepate.
Sources: en.wikipedia.org
=== Developmental stage === Adolescence is the period of greatest risk both for first use of an addictive drug and for the transition to disordered use. The prefrontal cortex, which supports planning, inhibitory control and the weighing of long-term consequences, develops more slowly than the brain's reward circuitry and is not fully mature until the mid-twenties. During this window sensitivity to reward is high while cognitive control is still developing, which contributes to greater risk-taking, including experimentation with drugs. Drug exposure in early adolescence can in turn disturb cortical development and delay prefrontal maturation, and prefrontal dysfunction in adolescents is itself associated with a higher risk of substance use disorder.
The main limitation of this technique for clinical applications is the high sensitivity to technical equipment and sample preparation techniques, which makes it difficult to construct large-scale databases. Attempts in this direction have however been made by Bruker with the IR Biotyper for food microbiology.
== Economy == Major employers in Lebanon include Lebanon Community School Corporation; the U.S. headquarters of German power tools company Festool and of Canadian specialty foods manufacturer Skjodt-Barrett; manufacturing plants for Hendrickson International, DS Smith, Kuraray, Kauffman Engineering, Maplehurst Bakeries, and D-A Lubricant Company; distribution centers for CNH Parts & Services, Subaru of America, Continental Tire the Americas, and Hachette Book Group USA; and health care and medical facilities operated by Witham Health Services. Lebanon is also the site of LEAP Research and Innovation District, an economic development initiative involving over 9,000 acres of land that will be allocated for technological and manufacturing projects. The area will be able to employ around 50,000 workers upon completion. Among the investments at LEAP is a $9 billion facility for Eli Lilly and Company that will produce active pharmaceutical ingredients for the antidiabetic medication Tirzepatide starting in late 2026.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.